GRAIL saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 76 to 83.
IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against that of all other stocks.
Over 100 years of market history shows that the top-performing stocks tend to have an 80 or better RS Rating as they begin their biggest runs.
Hone Your Stock-Picking Skills By Focusing On These Factors
While GRAIL is not near an ideal buy zone right now, see if it goes on to form and break out of a proper chart pattern.
GRAIL posted 0% earnings growth in the latest quarterly report, while sales growth came in at 38%.
GRAIL holds the No. 18 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Castle Biosciences and Guardian Pharmacy Svcs are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
